|Table of Contents|

Effects of LRRK2 on proliferation and drug resistance of breast cancer cells

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2022 06
Page:
979-985
Research Field:
Publishing date:

Info

Title:
Effects of LRRK2 on proliferation and drug resistance of breast cancer cells
Author(s):
LIU Jiuzhou; REN Shasha; LI Leilei
Department of Thyroid and Breast Surgery,Luoyang Central Hospital,Zhengzhou University,Henan Luoyang 471000,China.
Keywords:
LRRK2; breast cancer; TLR4/NF-κB pathway; proliferation; apoptosis; drug resistance
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2022.06.006
Abstract:
Objective:To investigate the expression of LRRK2 in breast cancer and its effect and molecular mechanism on the proliferation,apoptosis and drug resistance of breast cancer cells.Methods:Quantitative real-time PCR (qRT-PCR) and Western blot were used to detect the expression of LRRK2 in 48 breast cancer tissues and their matched normal tissues.The mRNA and protein expression levels of LRRK2 in human normal breast epithelial cells MCF-10A,breast cancer cell lines MCF-7,MDA-MB-231,BT-483,and adriamycin resistant cell lines MCF-7/ADR were detected.LRRK2 expression was interfered by transfection of si-LRRK2 sequence.CCK-8 assay and flow cytometry were used to detect the effect of knockdown LRRK2 on the proliferation activity,IC50 value and apoptosis of MCF-7 and MCF-7/ADR cells,respectively.The expressions of apoptosis-related proteins,drug-resistant proteins and proteins related to TLR4/NF-κB signaling pathway were detected by western blot.Results:The expression of LRRK2 in breast cancer tissues and cells was significantly higher than that in adjacent normal tissues and normal breast epithelial cells (P＜0.01).Compared with the blank control group and negative control siRNA group,the proliferation activity of MCF-7 and MCF-7/ADR cells in si-LRRK2 group was significantly inhibited,the apoptosis rate and the expression of apoptosis-related proteins Caspase-3 and Bax were significantly increased,and the expression of Bcl-2 was significantly decreased (P＜0.01).The IC50 value of MCF-7/ADR cells and the expression of drug-resistant protein P-gp in si-LRRK2 group were significantly decreased (P＜0.01),and the sensitivity of MCF-7/ADR cells to chemotherapy was significantly increased.In si-LRRK2 group,the levels of TLR4/NF-κB pathway related proteins TLR4,NF-κB p65,p-IKKβ and p-IκB phosphorylation were significantly decreased (P＜0.01),and the expression of inflammasome NLRP3 was also significantly decreased (P＜0.01). pcDNA3.1-TLR4 or pcDNA3.1-NLRP3 were co-transfected with si-LRRK2 group,and the inhibitory effect of LRRK2 on the proliferation and drug resistance of MCF-7/ADR cells and the pro-apoptotic effect of LRRK2 were significantly reversed (P＜0.05).Conclusion:LRRK2 is highly expressed in breast cancer tissues and cells,and knockdown of LRRK2 can inhibit the proliferation of breast cancer cells,induce cell apoptosis,and improve the sensitivity of drug-resistant cells to chemotherapy.LRRK2 may regulate P-gp expression by regulating TLR4/NF-κB signaling pathway and NLRP3 inflammasome,activate NLRP3 mediated inflammation pathway,participate in the biological behavior of breast cancer cells,and delay cell drug resistance.

References:

[1] DZAMKO NL.LRRK2 and the immune system［J］.Adv Neurobiol,2017,14(1):123-143.
[2] HARVEY K,OUTEIRO TF.The role of LRRK2 in cell signalling［J］.Biochem Soc Trans,2019,47(1):197-207.
[3]BERWICK DC,HEATON GR,AZEGGAGH S,et al.LRRK2 biology from structure to dysfunction:research progresses,but the themes remain the same［J］.Molecular Neurodegeneration,2019,14(1):49-61.
[4] HAN KA,YOO L,SUNG JY,et al.Leucine-rich repeat kinase 2(LRRK2) stimulates IL-1β-mediated inflammatory signaling through phosphorylation of RCAN1［J］.Front Cell Neurosci,2017,11（2）:125-136．
[5]丁雪冰,王雪晶,马明明,等.LRRK2在肾癌细胞中的表达及其对迁移能力的影响［J］.肿瘤基础与临床,2013,26(01):1-4. DING XB,WANG XJ,MA MM,et al.Expression of LRRK2 in renal cell carcinoma and its effect on migration ［J］.Tumor basis and clinic,2013,26(01):1-4.
[6]WEYGANT N,QU D,BERRY WL,et al.Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase 1［J］.Molecular Cancer,2014,13(1):103.
[7]LEBOVITZ C,CHOW N,LAM W,et al.Investigating a tumor suppressor role for Parkinson's susceptibility gene LRRK2 in lung cancer［J］.Cancer Research,2016,76(14):3668.
[8]孙晓冉，孙剑经，张林西，等.肿瘤多药耐药机制的研究进展［J］.现代肿瘤医学，2017,25（1）：164-166. SUN Xiaoran，SUN Jianjing，ZHANG Linxi,et al.Research progress of multidrug resistance in tumor［J］.Modern Oncology,2017,25（1）：164-166.
[9]沈丹华.分子生物学技术对于妇科肿瘤病理诊断及临床治疗的影响［J］.中国妇产科临床杂志,2019,20(04):289-291. SHEN DH.Effect of molecular biology on pathological diagnosis and clinical treatment of gynecological tumor ［J］.Chinese Journal of Obstetrics and Gynecology,2019,20(04):289-291.
[10] ZIMPRICH A,BISKUP S,LEITNER P,et al.Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology［J］.Neuron,2004,44(4):601-607．
[11] LIU Z,LEE J,KRUMMEY SM,et al.The kinase LRRK2 is a regulator of the transcription factor NFAT that modulates the severity of inflammatory bowel disease［J］.Nature Immunology,2016,12(11):1063-1070.
[12] WALLINGS RL,TANSEY MG.LRRK2 regulation of immune-pathways and inflammatory disease［J］.Biochem Soc Trans,2019,47(6):1581-1595.
[13] MOEHLE MS,WEBBER PJ,TSE T,et al.LRRK2 inhibition attenuates microglial inflammatory responses［J］.J Neurosci,2018,32(5):1602-1611.
[14] REGLODI D,RENAUD J,TAMAS A,et al.Novel tactics for neuroprotection in Parkinson's disease:Role of antibiotics,polyphenols and neuropeptides［J］.Prog Neurobiol,2017,155（3）:120-148.
[15] LIU Z,LEE J,KRUMMEY S,et al.The kinase LRRK2 is a regulator of the transcription factor NFAT that modulates the severity of inflammatory bowel disease［J］.Nat Immunol,2011,12(11):1063-1070．
[16] WALLINGS R,TANSEY MG.LRRK2 regulation of immune-pathways and inflammatory disease［J］.Biochem Soc Trans,2019,47(6):1581-1595.
[17] LIU Z,XU E,ZHAO HT,et al.LRRK2 and Rab10 coordinate macropinocytosis to mediate immunological responses in phagocytes［J］.EMBO J,2020,39(20):e104862.
[18]JUNG K,CHOI JS,KOO BM,et al.TM4SF4 and LRRK2 are potential therapeutic targets in lung and breast cancers through outlier analysis［J］.Cancer Res Treat,2020,53(1):9-24.
[19]GU S,CHEN J,ZHOU Q,et al.LRRK2 is associated with recurrence-free survival in intrahepatic cholangiocarcinoma and downregulation of LRRK2 suppresses tumor progress in vitro［J］.Dig Dis Sci,2019,65(4):1-9.
[20]YAKHINE-DIOP SMS .Autophagy:Cancer,other pathologies,inflammation,immunity,infection,and aging G2019S mutation of LRRK2 increases autophagy via MEK/ERK pathway［J］.Autophagy,2016,51（11）:123-142.
[21]吴娜,刘安立,余国行.乳腺癌耐药蛋白在肿瘤中的研究进展［J］.医学综述,2018,24(02):295-300. WU N,LIU AL,YU GX.Research progress of breast cancer resistance protein in cancer［J］.Medical Review,2018,24(02):295-300.
[22] BERWICK DC,HARVEY K.LRRK2 functions as a Wnt signaling scaffold,bridging cytosolic proteins and membrane-localized LRP6［J］.Human Mol Genet,2017,21(22):4966-4979.
[23] 姜一弘,张丹,张天择,等.核因子κB(NF-κB)信号通路在炎症与肿瘤中作用的研究进展［J］.细胞与分子免疫学杂志,2018,34(12):1130-1135. JIANG YH,ZHANG D,ZHANG TZ,et al.Progress in the role of nuclear factor κB(NF-κB) signaling pathway in inflammation and tumor［J］.Journal of Cell and Molecular Immunology,2018,34(12):1130-1135.
[24] SILVIA ALFONSO-LOECHES,JUAN URENA-PERALTA,M JOSé MORILLO-BARGUES,et al.Ethanol-induced TLR4/NLRP3 neuroinflammatory response in microglial cells promotes leukocyte infiltration across the BBB［J］.Neurochem Res,2016,41(1-2):193-209.
[25] QIAO Y,WANG P,QI J,et al.TLR-induced NF-κB activation regulates NLRP3 expression in murine macrophages ［J］.FEBS Lett,2012,586(7):1022-1026.
[26] ZHANG L,SUN D,BAO Y,et al.Nerolidol protects against LPS-induced acute kidney injury via inhibiting TLR4/NF-κB signaling［J］.Phytotherapy Research,2017,31(3):459.
[27]DENG GM,HE H,CHEN Z,et al.Lianqinjiedu decoction attenuates LPS-induced inflammation and acute lung injury in rats via TLR4/NF-κB pathway［J］.Biomed Pharmacother,2017,96（3）:148-152.

Memo

Memo:
河南省自然科学基金（编号：18PJ02369）
Last Update: 1900-01-01